The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting

Background/purpose Lenvatinib (an inhibitor of vascular endothelial growth factor (GF) receptors 1–3, fibroblast GF receptors 1–4, platelet-derived GF receptor α, rearranged during transfection, and stem cell factor receptor) was non-inferior to sorafenib in a phase 3 (REFLECT) trial of advanced hep...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hepatology international 2019-03, Vol.13 (2), p.199-204
Hauptverfasser:	Obi, Shuntaro, Sato, Takahisa, Sato, Shinpei, Kanda, Miho, Tokudome, Yuta, Kojima, Yuichiro, Suzuki, Yoji, Hosoda, Kenji, Kawai, Toshihiro, Kondo, Yuji, Isomura, Yoshihiro, Ohyama, Hiroshi, Nakagomi, Keiko, Ashizawa, Hiroshi, Miura, Yuko, Amano, Hiroyuki, Mochizuki, Hitoshi, Omata, Masao
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Body weight Colorectal Surgery Criteria Evaluation Fatigue Growth factors Hepatocellular carcinoma Hepatology Hypertension Liver cancer Medical treatment Medicine Medicine & Public Health Original Article Patients Proteinuria Receptors Safety Solid tumors Stem cell factor Stem cells Surgery Terminology Toxicity Transfection Tumors Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!